Anticoagulation in COVID-19: A systematic review, meta-analysis and rapid guidance from the mayo clinic
Date
2020Author
McBane, Robert D.
Torres Roldan, Victor D.
Niven, Alexander S.
Pruthi, Rajiv K.
Moreno Franco, Pablo
Linderbaum, Jane A.
Casanegra, Ana I.
Oyen, Lance J.
Houghton, Damon E.
Marshall, Ariela L.
Ou, Narith N.
Siege, Jason L.
Wysokinski, Waldemar E.
Padrnos, Leslie J.
Rivera, Candido E.
Flo, Gayle L.
Shamoun, Fadi E.
Silvers, Scott M.
Nayfeh, Tarek
Urtecho Suarez, Meritxell
Shah, Sahrish
Benkhadra, Raed
Mohir Saadi, Samer
Firwana, Mohamed
Jawaid, Tabinda
Amin, Mustapha
Prokop, Larry J.
Hassan Murad, M.
Metadata
Show full item record
Imagenes y Videos
Abstract
A higher risk of thrombosis has been described as a prominent feature of COVID-19. This
systematic review synthesizes current data on thrombosis risk, prognostic implications, and
anticoagulation effects in COVID-19. We included 37 studies from 4,070 unique citations.
Meta-analysis was performed when feasible. Coagulopathy and thrombotic events were
frequent among patients with COVID-19, and further increased in those with more severe
forms of the disease. We also present guidance on the prevention and management of
thrombosis from a multidisciplinary panel of specialists from the Mayo Clinic. The current
certainty of evidence is generally very low, and continues to evolve.
Link to resource
https://doi.org/10.1016/j.mayocp.2020.08.030Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.